Merck has three drugs currently under priority FDA review, one of them a Covid-19 drug:
Molnupiravir, an antiviral for Covid-19 which has received a positive opinion from the advisory board and which Merck's CEO says should work against any variant
Vaxneuvance, a pneumococcal vaccine
Lynparza, a breast cancer drug
Ciao traders ,
While my last shared BTC trade was a short, I was too busy with alt coins to follow that trade up with a long,
however, we're looking fairly strong on the higher tf's. I will buy a break of the upper resistance, as well as a potential retest of the 'stair' trendline.
CXRXF has been consolidating for a long time but now presents a low risk buy in. Notice the two trend lines, we are currently at the lower one. It could drop back 10% but I suspect even if it does, it will eventually drift towards the upper trend line. That's a nice 46% gain from here. Who knows, if it breaks the upper line it could really run.
My alert for NUMI's daily 12 EMA went off 12/21/2020 and have a tiny entry there. Wanted to add more to the 26 EMA (left) but missed it and it's seeing a solid 10-12% bounce from that. Hourly chart (right) looks like it could be setting up an hourly bear flag which has me cautious here. My position is very tiny; if doing swing trades on penny stocks I think it's...
I've been holding Merck since its big dip to $76 back in June. At the time I set a price target of $82:
However, I didn't sell at $82 and have continued to hold the stock due to strong fundamentals, technicals, news, and sentiment. Merck has positive earnings and sales growth, with PEG ratio...
Abbvie's volume has slackened somewhat after its recent triangle breakout, and it has broken its steep upward trendline. We may see a small correction late this month as Abbvie pulls back toward triangle top. However, if healthcare and pharmaceutical sector earnings continue to deliver this month (as they have so far), then Abbvie should get some buying volume...
AMEX:OGEN is going to rip into earnings then pull back right before then pop for 100% or more post earnings. Here are my price targets placed for the next week every few days starting with next Monday.
*1 drug for Oral Mucosis just finished Phase 2 trial, FULL data will be release on earnings call and ironically at the same time they have $15...
Successful completion of the pivotal Phase 3 program for Sci-B-Vac®, on-track for submission of regulatory approval applications in the U.S., Europe, and Canada expected to begin in Q4 2020
Announcement of pan-coronavirus vaccine candidate targeting COVID-19, SARS, and MERS – human clinical study material expected to be available in Q4 2020
We just checked pharmacies around the North East
PALFORZIA peanut allergy drug is available at CVS Pharmacy and is being filled at CVS Pharmacy
CVS Pharmacy is currently the largest pharmacy chain in the United States by number of locations with over 9,600 pharmacies throughout the United States.
Its parent company ranks as the 7th largest U.S. corporation by...
We bounced off of the line as I suspected might happen. I am expecting TLRY to at least retest the $180 dollar region if not make new all time highs. I would not put it past the market.
Would not recommend a short right now, confirmation is needed.
BL-8040 is a novel, short peptide that functions as a high-affinity antagonist for CXCR4, which BioLineRx is developing for the treatment of solid tumors, acute myeloid leukemia, or AML, and stem-cell mobilization for bone-marrow transplantation.
In January 2016, BioLineRx entered into a collaboration with MSD, known as ...